Inhibrx Biosciences, Inc.INBX
Oncology5 cited findings · profile updated 2026-08-20
101.48 USDnot live — refreshed daily
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. (INBX) is an oncology-focused research site. The company's portfolio includes ozekibart, which has been accepted for filing in the United States for the potential approval indication of conventional chondrosarcoma. Another key drug, INBRX-106, is currently in Phase 2 development for head and neck squamous cell carcinoma (HNSCC) and is being studied as a combination therapy with pembrolizumab.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| BLA acceptance | accepted for filing for ozekibart | Inhibrx Biosciences, Inc. — SEC 8-K (2026-08-13), p.1 |
| Potential approval indication | conventional chondrosarcoma for ozekibart | Inhibrx Biosciences, Inc. — SEC 8-K (2026-08-13), p.1 |
| Phase | Phase 2 for INBRX-106 | Inhibrx Biosciences, Inc. — SEC 8-K (2026-08-13), p.1 |
| Indication | head and neck squamous cell carcinoma (HNSCC) for INBRX-106 | Inhibrx Biosciences, Inc. — SEC 8-K (2026-08-13), p.1 |
| Combination therapy | pembrolizumab with INBRX-106 | Inhibrx Biosciences, Inc. — SEC 8-K (2026-08-13), p.1 |
Key projects
- ozekibart (conventional chondrosarcoma) — United States
BLA acceptance for ozekibart was accepted for filing in the United States for the potential approval indication of conventional chondrosarcoma.
- INBRX-106 (head and neck squamous cell carcinoma)
INBRX-106 is in Phase 2 development for head and neck squamous cell carcinoma (HNSCC) as a combination therapy with pembrolizumab.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →